{"schema_version":"1","generated_at":"2026-10-28T12:14:06.975Z","data_as_of":null,"url":"https://www.findmykol.com/kol/brett-brinker","json_url":"https://www.findmykol.com/kol/brett-brinker/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"brett-brinker","name":"Brett Brinker","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Grand Rapids","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1750347290","orcid":"0000-0003-2139-7820","openalex":"A5079310177"},"summary":"Brett Brinker is an Oncology physician. OpenAlex indexes 39 publications with 495 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":39,"cited_by_count":495,"h_index":9,"latest_activity_year":2025,"emerging":true,"source":"works"},"payments":{"company_count":25,"program_years":{"first":2021,"last":null},"rows_total":38,"shown":3,"withheld":35,"rows":[{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":96.74,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750347290"},{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":63.59,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750347290"},{"payer":"KYOWA KIRIN, INC.","program_year":2025,"amount_usd":29.93,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750347290"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1750347290","source":"payments"},"publications":{"total":39,"shown":5,"withheld":34,"matched_by":"OpenAlex author record","recent":[{"title":"Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-1800","status":"verified"},{"title":"Supplementary Figure S4 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine","year":2025,"source_url":"https://doi.org/10.1158/1078-0432.30706127","status":"verified"},{"title":"Supplementary Figure S2 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine","year":2025,"source_url":"https://doi.org/10.1158/1078-0432.30706133","status":"verified"},{"title":"Supplementary Figure S1 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine","year":2025,"source_url":"https://doi.org/10.1158/1078-0432.30706136","status":"verified"},{"title":"Supplementary Figure S3 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine","year":2025,"source_url":"https://doi.org/10.1158/1078-0432.30706130","status":"verified"}],"source":"works"},"contact":{"address_1":"145 MICHIGAN ST NE STE 3100","city":"Grand Rapids","state":"MI","zip":"495032563","phone":"616-954-9800","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1750347290","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":35,"publications":34}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-03-13","provider_certified":"2020-03-13","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}